Fennec Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FRX.TO research report →
Price Chart
About the company
Fennec Pharmaceuticals Inc. , a biopharmaceutical firm established in 1996, operates from its base in Research Triangle Park, North Carolina. The company's lead investigational compound, PEDMARK, is a sodium thiosulfate formulation currently undergoing clinical development.
- CEO
- Jeffrey S. Hackman
- IPO
- 2001
- Employees
- 35
- HQ
- Research Triangle Park, NC, US
Get TickerSpark's AI analysis on FRX.TO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $542.94M
- P/E
- -87.31
- Fwd P/E
- 54.47
- PEG
- -1.56
- P/S
- 6.66
- P/B
- 9.24
- EV/EBITDA
- -148.58
- Div Yield
- 0.00%
- Gross Margin
- 93.73%
- Op Margin
- -1.96%
- Net Margin
- -5.49%
- ROE
- -11.71%
- ROIC
- -1.84%
Latest fiscal year · YoY change
- Revenue
- $44.64M-6.1%
- Gross Profit
- $40.88M-7.8%
- Op Income
- $-6,346,000
- Net Income
- $-9,741,000-2134.2%
- EPS
- $-0.34-1600.0%
- OCF Growth
- -154.4%
- FCF Growth
- -154.4%
- 52W High
- $17.64
- 52W Low
- $7.59
- 50D MA
- $14.60
- 200D MA
- $11.66
- Beta
- 1.07
- RSI (14)
- 52
- Avg Volume
- 758
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Get the FRX.TO Q2 '26 earnings-call summary
Create a free account to generate an AI summary of this call — key takeaways, results & guidance, CEO/CFO commentary, Q&A, and a bull vs bear read. Ready in about a minute, and it'll be live for everyone.
Create free account →Already have an account? Log in
- Free Float
- 48.4%
- Shares Outstanding
- 34.74M
- Float Shares
- 16.83M
Held by 37 ETFs
Biggest fund positions in FRX.TO by dollar value.
Our FRX.TO coverage
Recent articles, reports, and earnings notes.
No research on FRX.TO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FRX.TO report →Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers
globenewswire.com · Feb 20
Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
globenewswire.com · Dec 9
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
globenewswire.com · Nov 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.